Discover

BLCO
Bausch + Lomb Corporation
15.99
1 x 15.99
1 x 18.45
bid
ask
+
0.01
0.06%
1 @ 04:00 PM
16.00 +0.01 (0.06%)
Ytd-6.38%
1y14.79%
15.74
day range
16.06
13.09
52 week range
18.91
Open15.74Prev Close15.98Low15.74High16.06Mkt Cap5.70B
Vol404.03KAvg Vol456.96KEPS0.65P/E24.60Forward P/E14.37
Beta0.56Short Ratio8.80Inst. Own11.02%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning07-2950-d Avg15.89200-d Avg16.271yr Est18.14
Earning
DateForEstimateReportedSurprisesurprise %
2026-07-292026-060.16N/AN/AN/A
2026-04-292026-030.060.080.0233.33%
2026-02-182025-120.350.32-0.03-8.57%
2025-10-292025-090.160.180.0212.50%
2025-07-302025-060.060.070.0116.67%
2025-04-302025-030.03-0.07-0.1-333.33%
Upgrade / Downgrade
DateFirmActionFromTo
2026-07-06Evercore ISI GroupUpgradeIn-LineIn-Line
2026-04-30Evercore ISI GroupUpgradeIn-LineIn-Line
2026-04-06Evercore ISI GroupUpgradeIn-LineIn-Line
2026-02-23HC Wainwright & Co.UpgradeBuyBuy
2026-02-19CitigroupUpgradeBuyBuy
2026-02-19BarclaysUpgradeEqual-WeightEqual-Weight
Profile
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.
Insider Holder
DateNameRelationQuantityDescription
2026-03-05BAILEY AMBROSE ROBERT DOUGLAS J.D.Officer246.49KStock Award(Grant)
2026-02-24BONNEFOY LUCOfficer117.94KStock Award(Grant)
2026-03-05ELDESSOUKY OSAMA AChief Financial Officer407.13KStock Award(Grant)
2026-03-05ELDESSOUKY SAMChief Financial Officer407.13KStock Award(Grant)
2026-02-24HASHAD YEHIAOfficer198.91KStock Award(Grant)
2026-02-24MUNSCH FREDERICK JOHNOfficer108.48KStock Award(Grant)
Institution Ownership
Report DateOrganizationPositionValuePercentage
2026-03-30Deutsche Bank AG3.53M0.000.99%
2026-03-30ICAHN CARL C3.50M0.000.98%
2026-03-30Oaktree Capital Management LLC3.38M0.000.95%
2026-03-30D. E. Shaw & Co LP3.15M0.000.88%
2026-03-30Goldentree Asset Management LP2.66M0.000.75%
2026-03-30Silver Point Capital LP2.25M0.000.63%
Fund Ownership
Report DateOrganizationPositionValuePercentage
2026-04-29T. Rowe Price High Yield556.54K0.000.16%
2026-03-30T. Rowe Price High Yield Bond556.54K0.000.16%
2026-03-30T. Rowe Price High Yield Trust - D273.62K0.000.08%
2025-12-30Bestinver Norteamérica FI256.11K0.000.07%
2026-04-29Ballast SMidCap152.03K0.000.04%
2026-05-28Ballast Small/Mid Cap ETF150.98K0.000.04%